If ozekibart makes it to market, it could face competition from Servier Pharmaceuticals’ IDH inhibitor, Tibsovo (ivosidenib), which is currently in Phase III for conventional chondrosarcoma. Bristol ...
IDH1 inhibitors show strong efficacy and tolerability in IDH1-mutated AML and MDS, with some patients achieving long-term ...
This article describes two pediatric SM with AML1::ETO+ AML patients induced by novel KIT exon11 mutations not previously documented in medical literature. Both patients underwent allogeneic ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback